AI-Bio
A real lab-in-the-loop antibody-engineering shop with blue-chip pharma validation (AbbVie/Lilly/Merck/Amgen) and now its own clinic-bound ADC — but it is dramatically out-capitalized ($145M vs. $1B+ peers) and is becoming a Lilly satellite; WATCHING as a private, with the IND-into-clinic 2026 prints as the only catalyst that re-rates it.
Research
The verdict
A real lab-in-the-loop antibody-engineering shop with blue-chip pharma validation (AbbVie/Lilly/Merck/Amgen) and now its own clinic-bound ADC — but it is dramatically out-capitalized ($145M vs. $1B+ peers) and is becoming a Lilly satellite; WATCHING as a private, with the IND-into-clinic 2026 prints as the only catalyst that re-rates it.
BigHat Biosciences is a San Mateo, CA antibody-engineering company founded in 2019 by Mark DePristo (then-CEO) and Peyton Greenside (now CEO) . The product is **Milliner™** — a "full-stack" antibody discovery and engineering platform that fuses **machine learning** with a **synthetic-biology-based, automated high-speed wet lab** to run rapid **closed-loop design-build-test cycles** . The thesis is explicitly not "AI designs the molecule in a vacuum" — it is "AI proposes, the in-house automated lab measures, the data trains the next round," optimizing antibodies on multiple axes at once (affinity, developability, manufacturability, safety/immunogenicity).
How it makes money — two engines:
The only disclosed deal economics are the AbbVie terms: $30M upfront, up to ~$325M in aggregate R&D milestones, plus commercial milestones and tiered royalties ``. All other deal values are undisclosed.
For a clinical-stage biotech the "supply chain" is the build-and-make stack: who supplies the science inputs, who manufactures the drug, who runs the trials.
Upstream (design inputs) → BigHat → drug → patient:
Named-stakeholder verdict: the chain is real and named — Synaffix/Lonza (chemistry + manufacturing), Lilly Catalyze360 (development scaffolding), AbbVie/Lilly/Merck/Amgen (demand for the platform). The single most important dependency is Synaffix/Lonza for the lead asset.
The moat is the lab-in-the-loop, not the model. Greenside's own framing (Lens 12) is that anyone can generate a sequence; the durable asset is the proprietary experimental data flywheel — a high-throughput automated wet lab generating consistent, multi-parameter measurements that train models competitors can't replicate from public data ``. Specific moat sources:
Bargaining power: weak-to-balanced and structurally deteriorating. BigHat needs big pharma's capital and clinical machinery more than they need any single AI-antibody shop (there are ~6 credible competitors). The Lilly relationship — equity investment + two-program discovery deal + TuneLab data deal + Catalyze360 development support — is deep validation but also concentration risk (see Lens 13). A moat that depends on staying the preferred partner of one giant is a moat with a landlord.
n/a — private, not disclosed. BigHat does not report segments. Directionally , ~all near-term revenue is **collaboration/milestone revenue** from pharma partnerships (AbbVie's $30M upfront is the only hard datapoint); proprietary-pipeline revenue is **$0** (pre-clinical). A third-party aggregator lists **"2023 revenue $30M"** — this is unaudited and almost certainly the AbbVie upfront recognized, not recurring product revenue; treat as a one-time collaboration inflow, not a run-rate. No geographic split disclosed.
The asset table is the company. As of mid-2026 ``:
| Program | Modality | Indication | Stage | Next milestone | Rights |
|---|---|---|---|---|---|
| Lead ADC | Next-gen ADC (Synaffix GlycoConnect/HydraSpace/toxSYN) | GI cancers | IND-enabling → clinic 2026 | First-in-human start, 2026 | BigHat, full global rights (Lilly Catalyze360 support) |
| TCE | Avidity-driven T-cell engager | Solid tumors | Pre-IND | IND filing 2026 | BigHat (proprietary) |
| AbbVie collab | Antibodies | Oncology + neuroscience | Discovery | Undisclosed | AbbVie-led, BigHat royalties |
| Lilly collab | Antibodies (≤2 programs) | Undisclosed | Discovery | Undisclosed | Lilly-led + Lilly equity in BigHat |
| Merck collab | Antibodies (≤3 programs) | Undisclosed | Discovery | Undisclosed | Merck-led |
| Amgen collab | Single-domain antibodies | Undisclosed | Stage 1 complete | Undisclosed | Amgen-led |
PoS / readout reality: these are pre-clinical to phase-entry assets — there is no human efficacy data yet and therefore no meaningful probability-of-success beyond generic IND-to-approval base rates (~7–10% for oncology, lower for first-in-class) ``. The lead ADC is BigHat's first-ever clinical candidate — 2026 is the year it stops being a platform-only story. The entire near-term thesis rides on the GI-cancer ADC actually entering the clinic in 2026 on schedule and the TCE IND landing.
No earnings calls. The substitute signal is founder communication + strategic posture, and it is unusually legible:
Multiples are meaningless for a private pre-revenue biotech. The two relevant comps are (a) catalysts and (b) capitalization vs. the AI-antibody peer set.
Catalyst calendar (``):
Capitalization vs. AI-antibody peer set — BigHat is badly out-gunned ``:
| Company | Total raised | Latest valuation | Posture |
|---|---|---|---|
| BigHat | ~$145M (8 rounds) | n/a — not disclosed | Lab-in-the-loop + pharma deals + own ADC |
| Xaira Therapeutics | $1B+ (launch) | n/a | David Baker / RFdiffusion; ARCH+Foresite |
| Generate:Biomedicines | >$1B cumulative | n/a (Novartis-partnered) | Generative protein platform |
| Chai Discovery | >$225M | $1.3B (Series B) | De-novo (Chai-2, ~20% hit rate) |
| Absci | Public (NASDAQ: ABSI) | ~public micro/small-cap | Generative + AstraZeneca |
| Nabla Bio | ~$26M Series A (2024) | n/a | AZ/BMS/Takeda, >$550M bio-bucks |
The peer table's single loudest fact: BigHat has raised roughly one-seventh of what Xaira and Generate command, and ~1/9th of Chai's valuation alone. Its edge has to be capital efficiency and real lab data, because it cannot win a spending war.
No stock to move. The events that re-rated BigHat's standing (``):
Pattern: the market (here = pharma counterparties + VCs) reacts to (1) disclosed deal economics and (2) Lilly's escalating commitment. The trajectory is up-and-to-the-right on validation, but every recent up-tick has Lilly's name on it — concentration the bear case will seize on.
Accounting: n/a — private, unaudited, no financial statements disclosed. There is no income statement, balance sheet, or cash-flow statement to forensically examine — this absence is itself the disclosure-quality caveat for any investor. The one third-party "2023 revenue $30M" figure `` is unaudited and should be read as the AbbVie upfront, not run-rate revenue (Lens 4). Cash, burn, and runway are undisclosed — the single biggest information gap in the file (see Lens 11).
Regulatory findings (required sub-section):
regulatory/regulatory-findings.md (Step 0): BigHat has no CIK — not an SEC filer; no EDGAR enforcement search possible. Zero SEC findings ``."BigHat Biosciences" (FTC OR DOJ OR FDA OR lawsuit OR litigation OR settlement) returned no material hits attributable to BigHat ``.n/a — no 10-K (private).Science/exclusivity (clinical overlay sub-section):
No EPS to project (private, pre-revenue). forecast.ts create step skipped (watchlist breadth rule + no scoreable EPS/binary readout date disclosed). The two questions that matter:
(a) Runway to the next value-inflection catalyst. Cash and burn are undisclosed . What we know: ~$145M raised over 8 rounds through Apr 2025, with a Lilly equity tranche (~$45M, per aggregators) being the most recent . Headcount ~98–99 (PitchBook/Tracxn, early 2026) vs. 37 at the 2022 Series B — roughly tripled. A ~100-person antibody shop running an automated wet lab + IND-enabling work typically burns ~$40–70M/yr; against ~$145M raised plus undisclosed milestone inflows (AbbVie $30M up + ongoing), runway plausibly reaches the 2026 clinic-entry catalysts but likely requires a fresh raise (Series C) in 2026–27 to fund a Phase 1 — the financing watch-item. Partner milestones partially offset burn but are lumpy and undisclosed.
(b) IPO-readiness. private-watch.json absent — no stored readiness grade. `` BigHat is not IPO-imminent: no clinical data, a funding winter for early biotech, and a private market that is still funding it. S-1 unlocks would require (1) the lead ADC posting clean Phase 1 safety/early-efficacy, and (2) a friendlier biotech IPO window — earliest realistic 2027–28, and an M&A/acqui-partner outcome (Lilly the obvious acquirer) is at least as likely as an IPO. Action for the be-early ledger: BigHat should be added to research/private-watch.json (currently missing) with stage = "clinical-entry 2026", readiness = low-but-rising, catalyst = "GI ADC FIH + TCE IND".
Bull case. BigHat is the disciplined adult of the AI-antibody class. While Xaira ($1B) and Generate (>$1B) raise on de-novo-design spectacle, BigHat built a real automated wet lab that generates the proprietary, multi-parameter data that is the actual scarce asset — and it proved that data is valuable by (a) signing AbbVie/Lilly/Merck/Amgen and (b) having Lilly want its data for a foundation model (TuneLab). It did this on ~$145M — ~1/7th of peers — and is now converting platform credibility into owned drugs (GI ADC to clinic 2026, TCE IND 2026) while keeping global rights. If the lead ADC reads out clean, BigHat re-rates from "services platform" to "clinical-stage oncology company with an AI engine," and the Lilly relationship becomes an obvious M&A on-ramp.
Bear case (permanent-impairment risks).
Pre-mortem (18 months out, thesis broke): the GI ADC's clinic entry slipped past 2026 (IND-enabling tox or CMC delay on the Synaffix-derived ADC), the TCE IND also slipped, no Series C closed in a frozen biotech market, a foundation-model competitor (Lilly's own TuneLab, ironically, or Chai/Xaira) commoditized "developability prediction," and BigHat quietly became a fee-for-service CRO with a famous logo — or sold to Lilly at a down-round mark.
Are multiples too high? n/a — private, no public multiple. The relevant question is whether the last private mark (undisclosed) prices in clinical success that hasn't happened — unknowable without the cap table.
Contrarian view (what the market refuses to see): The crowd sorts AI-bio by raise size and de-novo hit-rate (Xaira/Chai win that contest). What it under-weights is that the binding constraint in antibody drugs is downstream wet-lab validation and developability, not sequence generation — exactly BigHat's lane — and that a company spending 1/7th as much while landing the same pharma logos is demonstrating capital efficiency the spenders are not. If the field's bubble deflates (the StatNews skeptic thread), the survivor may be the one that always insisted the lab — not the model — is the moat.
Dismantling the bull case:
A fortress-margin vertical-SaaS monopoly trading at a growth-stock funeral price (~20x forward EPS, near 52-wk lows) because the market is pricing a Salesforce-Agentforce CRM war that threatens the contested ~40% (Commercial) while ignoring the defensible, faster-growing ~60% (R&D/Quality); BULLISH at $153 on a 1–3Y view, but the CRM-migration-to-2030 is a real, watchable execution overhang — not a phantom.
A real, fast-growing oncology-data + diagnostics franchise wrapped in an "AI" narrative it can't yet monetize — own the genomics flywheel, but the round-trip-flavored deals, 30-vote founder, and a CEO famous for cashing out cap the multiple until cash flow turns.
Not a tools company anymore — a sub-NAV cash shell mid-conversion into Treeline's oncology pipeline; the only edge is the deal-spread between ~$325M market cap and the ~$460M net cash being delivered, and that spread is a bet on Bilenker's KRAS/BCL6 readouts, not on CyTOF.